BR0206273A - testes diagnósticos para caracterizar o risco de um paciente humano de desenvolver ou apresentar doença cardiovascular e para avaliar um agente terapêutico para doença cardiovascular em um sujeito suspeito de apresentar ou apresentando doença cardiovascular, e, kit - Google Patents
testes diagnósticos para caracterizar o risco de um paciente humano de desenvolver ou apresentar doença cardiovascular e para avaliar um agente terapêutico para doença cardiovascular em um sujeito suspeito de apresentar ou apresentando doença cardiovascular, e, kitInfo
- Publication number
- BR0206273A BR0206273A BRPI0206273-9A BR0206273A BR0206273A BR 0206273 A BR0206273 A BR 0206273A BR 0206273 A BR0206273 A BR 0206273A BR 0206273 A BR0206273 A BR 0206273A
- Authority
- BR
- Brazil
- Prior art keywords
- mpo
- presenting
- cardiovascular disease
- subject
- risk
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/26—Processes using, or culture media containing, hydrocarbons
- C12N1/28—Processes using, or culture media containing, hydrocarbons aliphatic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Primary Health Care (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
"TESTES DIAGNóSTICOS PARA CARACTERIZAR O RISCO DE UM PACIENTE HUMANO DE DESENVOLVER OU APRESENTAR DOENçA CARDIOVASCULAR E PARA AVALIAR UM AGENTE TERAPêUTICO PARA DOENçA CARDIOVASCULAR EM UM SUJEITO SUSPEITO DE APRESENTAR OU APRESENTANDO DOENçA CARDIOVASCULAR, E, KIT". Testes diagnósticos para caracterizar o risco de um indivíduo de desenvolver ou apresentar uma doença cardiovascular. Em uma concretização, o presente teste diagnóstico compreende determinar o níVel de atividade de mieloperoxidase (MPO) em uma amostra corporal obtida do indivíduo ou sujeito de teste. Em outra concretização, o teste diagnóstico compreende determinar o nível de massa de MPO em uma amostra corporal obtida do sujeito de teste. Em outra concretização, o teste diagnóstico compreende determinar o nível de um ou mais produtos de oxidação gerados por MPO selecionados em uma amostra corporal obtida do sujeito de teste. Os produtos de oxidação gerados por MPO selecionados são ditirosina, nitrotirosina, sulfóxido de metionina ou um produtos de peroxidação de lipídeos gerados por MPO. Em seguida, compara-se níveis de atividade de MPO, de massa de MPO, ou o produto de oxidação gerado por MPO selecionado em amostras corporais do sujeito de teste com um valor predeterminado que é derivado de medições de atividade de MPO, massa de MPO, ou do produto de oxidação gerado por MPO selecionado em amostras corporais comparáveis obtidas da população em geral ou de uma população selecionada de sujeitos humanos. Uma comparação desse tipo caracteriza o risco do sujeito de desenvolver CVD.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25934001P | 2001-01-02 | 2001-01-02 | |
US28343201P | 2001-04-12 | 2001-04-12 | |
PCT/US2002/000050 WO2002062207A2 (en) | 2001-01-02 | 2002-01-02 | Myeloperoxidase, a risk indicator for cardiovascular disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0206273A true BR0206273A (pt) | 2006-11-21 |
Family
ID=26947248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0206273-9A BR0206273A (pt) | 2001-01-02 | 2002-01-02 | testes diagnósticos para caracterizar o risco de um paciente humano de desenvolver ou apresentar doença cardiovascular e para avaliar um agente terapêutico para doença cardiovascular em um sujeito suspeito de apresentar ou apresentando doença cardiovascular, e, kit |
Country Status (8)
Country | Link |
---|---|
US (10) | US7223552B2 (pt) |
EP (1) | EP1353666B1 (pt) |
AU (1) | AU2002249893B2 (pt) |
BR (1) | BR0206273A (pt) |
CA (1) | CA2440978C (pt) |
DK (1) | DK1353666T3 (pt) |
ES (1) | ES2429528T3 (pt) |
WO (1) | WO2002062207A2 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1353666T3 (da) * | 2001-01-02 | 2013-10-14 | Cleveland Clinic Foundation | Myeloperoxidase, en risikoindikator for cardiovasculær sygdom |
US7780950B2 (en) | 2002-01-02 | 2010-08-24 | The Cleveland Clinic Foundation | Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents |
CA2481941A1 (en) | 2002-04-17 | 2003-10-30 | The Cleveland Clinic Foundation | Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents |
US20050048660A1 (en) * | 2003-09-02 | 2005-03-03 | Case Western Reserve University | Biomarker of maternal alcohol use during pregnancy |
US7459286B1 (en) | 2003-10-22 | 2008-12-02 | The Cleveland Clinic Foundation | Assessing the risk of a major adverse cardiac event in patients with chest pain |
WO2005055810A2 (en) | 2003-12-05 | 2005-06-23 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
US20050244892A1 (en) * | 2004-02-27 | 2005-11-03 | Lazar Mitchell A | Resistin as a marker and therapeutic target for cardiovascular disease |
US7306562B1 (en) | 2004-04-23 | 2007-12-11 | Medical Software, Llc | Medical risk assessment method and program product |
US8852879B2 (en) * | 2004-04-29 | 2014-10-07 | The Children's Hospital Of Philadelphia | Materials and methods for the detection of nitrated fibrinogen |
US20050244905A1 (en) * | 2004-04-29 | 2005-11-03 | Harry Ischiropoulos | Nitrated fibrinogen as a marker for coronary artery disease and rapid blood clot formation |
CA2581929C (en) * | 2004-07-19 | 2016-10-18 | University Of Washington | Methods for assessing the risk for development of cardiovascular disease |
US7378396B2 (en) | 2004-08-11 | 2008-05-27 | The Cleveland Clinic Foundation | Therapeutic agents and methods for cardiovascular disease |
US7195891B2 (en) * | 2004-08-11 | 2007-03-27 | General Atomics | Methods and compositions of enzymatic cycling based assays for myeloperoxidase |
US20060183174A1 (en) * | 2005-02-11 | 2006-08-17 | Leong Ng | Diagnosis |
US7972802B2 (en) * | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
US20080171344A1 (en) * | 2006-12-22 | 2008-07-17 | Kapsner Kenneth P | Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase |
US20080286818A1 (en) * | 2007-05-18 | 2008-11-20 | Datwyler Saul A | Blood sample handling methods for improved assays for myeloperoxidase |
WO2009023331A2 (en) * | 2007-05-18 | 2009-02-19 | Abbott Laboratories | Antibodies and improved test sample handling methods for use in assays for myeloperoxidase |
US20090148866A1 (en) * | 2007-05-18 | 2009-06-11 | Abbott Laboratories | Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase |
US20090134325A1 (en) * | 2007-11-27 | 2009-05-28 | Goldman Mildred M | Methods for detecting estradiol by mass spectrometry |
US8916385B2 (en) | 2007-12-13 | 2014-12-23 | Quest Diagnostics Investments, Inc. | Methods for detecting estrone by mass spectrometry |
US20090162876A1 (en) * | 2007-12-20 | 2009-06-25 | Abbott Laboratories | Myeloperoxidase assays |
US20090208992A1 (en) * | 2008-02-20 | 2009-08-20 | The Cleveland Clinic Foundation | Paraoxonase 1 enzymatic activity, a risk indicator for major adverse cardiovascular events |
US20110201947A1 (en) * | 2008-03-14 | 2011-08-18 | The Cleveland Clinic Foundation | Oxidized paraoxonase 1 and paraoxonase 1/hdl particle number ratio as risk markers for cardiovascular disease |
US8241861B1 (en) | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
WO2010147952A1 (en) * | 2009-06-15 | 2010-12-23 | The Cleveland Clinic Foundation | Methylated arginine metabolites as risk predictors of cardiovascular disease |
US20110034419A1 (en) * | 2009-06-27 | 2011-02-10 | Musc Foundation For Research Development | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease |
WO2011100426A2 (en) * | 2010-02-10 | 2011-08-18 | Cleveland Heartlab Llc | Compositons and methods for predicting cardiovascular events |
EP2366431A1 (en) | 2010-03-19 | 2011-09-21 | Universitätsklinikum Hamburg-Eppendorf | Myeloperoxidase as a target in atrial fibrillation |
US20110287468A1 (en) | 2010-04-19 | 2011-11-24 | General Atomics | Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples |
JP5337096B2 (ja) | 2010-04-28 | 2013-11-06 | 株式会社日立製作所 | 動脈硬化の評価法 |
ES2455124T5 (es) | 2010-05-05 | 2018-05-08 | Zora Biosciences Oy | Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca |
CN103154742B (zh) | 2010-06-20 | 2017-11-21 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
GB201021509D0 (en) * | 2010-12-20 | 2011-02-02 | Reactivlab Ltd | Assay method |
KR101660328B1 (ko) | 2014-01-14 | 2016-09-27 | 한국과학기술연구원 | 심혈관 질환 진단용 바이오 마커 |
WO2017172934A1 (en) | 2016-04-01 | 2017-10-05 | Cardiac Pacemakers, Inc. | Alert management for physiological event detection |
RU2019109212A (ru) * | 2016-09-01 | 2020-10-01 | Дзе Джордж Вашингтон Юниверсити | Рнк-биомаркеры крови ишемической болезни сердца |
KR102003309B1 (ko) | 2016-12-05 | 2019-07-25 | 한국과학기술연구원 | 대사체 및 임상지표를 활용한 관상동맥 심장질환 진단용 키트 및 기초 정보 제공 방법 |
US20180168779A1 (en) * | 2016-12-19 | 2018-06-21 | Sten R. Gerfast | Anchoring system for prosthetics |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2765299A (en) * | 1952-06-27 | 1956-10-02 | Armour & Co | Recovery of serum albumin |
US5846799A (en) * | 1988-06-14 | 1998-12-08 | La Region Wallone | Human myeloperoxidase and its therapeutic application |
US5460961A (en) * | 1988-06-14 | 1995-10-24 | La Region Wallonne | Human myeloperoxidase and its therapeutic application |
FR2644894B1 (fr) * | 1989-03-24 | 1994-05-13 | Sanofi | Trousse et methode de dosage enzymatique applicables a des cellules entieres |
IT8921788A0 (it) | 1989-09-21 | 1989-09-21 | Diesse Diagnostica | Reattivo utile per la rilevazione e la determinazione quantitativa dei leucociti in fluidi biologici. |
US5200319A (en) * | 1989-10-27 | 1993-04-06 | The General Hospital Corporation | Diagnosis of glomerulonephritis |
US5604105B1 (en) | 1990-10-12 | 1999-08-24 | Spectral Diagnostics Inc | Method and device for diagnosingand distinguishing chest pain in early onset thereof |
US5776892A (en) * | 1990-12-21 | 1998-07-07 | Curative Health Services, Inc. | Anti-inflammatory peptides |
US5122534A (en) * | 1991-02-08 | 1992-06-16 | Pfizer Inc. | Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides |
US6962795B1 (en) * | 1992-05-11 | 2005-11-08 | Dendreon Corporation | Neutrophil inhibitors |
US6191169B1 (en) * | 1992-08-28 | 2001-02-20 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
WO1996004311A1 (en) * | 1994-08-03 | 1996-02-15 | University Of Alabama At Birmingham Research Foundation | Monoclonal antibody to nitrotyrosine, methods for diagnosis and methods for treatment of disease |
US5871946A (en) * | 1995-05-18 | 1999-02-16 | Coulter Corporation | Method for determining activity of enzymes in metabolically active whole cells |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
US6268220B1 (en) * | 1996-09-09 | 2001-07-31 | Washington University | Diagnostic method for atherosclerosis |
US5731208A (en) * | 1996-09-09 | 1998-03-24 | Washington University | Method of detecting conditions indicative of atherosclerosis |
US5874313A (en) * | 1997-03-25 | 1999-02-23 | Oy Aboatech Ab | Method for quantifying oxidation parameters of low density lipoproteins and use thereof |
ATE530180T1 (de) | 1997-04-02 | 2011-11-15 | Brigham & Womens Hospital | Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen |
US7030152B1 (en) * | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6133039A (en) * | 1998-02-09 | 2000-10-17 | Washinton University | In vivo method for determination of oxidative stress |
US6096556A (en) * | 1998-02-09 | 2000-08-01 | Washington University | Method for the determination of oxidative stress |
US6953666B1 (en) * | 1998-11-06 | 2005-10-11 | Emory University | Biomarkers for oxidative stress |
JP4485070B2 (ja) * | 1999-03-29 | 2010-06-16 | 旭化成株式会社 | 全血試料の白血球数を定量する方法 |
JP4344136B2 (ja) | 2000-11-10 | 2009-10-14 | エフ・ホフマン−ラ・ロシュ・リミテッド | アポリポタンパク質類似体 |
AU3084802A (en) | 2000-12-14 | 2002-06-24 | Brigham & Womens Hospital | Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes |
BE1013881A6 (fr) * | 2000-12-21 | 2002-11-05 | Univ Bruxelles | Fractions de ldl oxydees, procede d'obtention et utilisation a but diagnostique ou therapeutique. |
DK1353666T3 (da) | 2001-01-02 | 2013-10-14 | Cleveland Clinic Foundation | Myeloperoxidase, en risikoindikator for cardiovasculær sygdom |
US20030008373A1 (en) | 2001-04-17 | 2003-01-09 | Myriad Genetics, Incorporated | APOA1-interacting proteins and use thereof |
CA2344007A1 (en) * | 2001-04-12 | 2002-10-12 | Michael R. Buchanan | Cardiovascular disease and thrombotic risk diagnostic tests |
WO2003026651A1 (en) * | 2001-09-28 | 2003-04-03 | Indevus Pharmaceuticals, Inc. | Method of inhibiting the production and/or effects of intestinal pro-inflammatory cytokines, prostaglandins and others |
US20120129708A1 (en) * | 2010-05-19 | 2012-05-24 | Cleveland Heart Lab | Compositions and methods for predicting cardiovascular events |
-
2002
- 2002-01-02 DK DK02718773.1T patent/DK1353666T3/da active
- 2002-01-02 ES ES02718773T patent/ES2429528T3/es not_active Expired - Lifetime
- 2002-01-02 US US10/039,753 patent/US7223552B2/en not_active Expired - Lifetime
- 2002-01-02 BR BRPI0206273-9A patent/BR0206273A/pt not_active IP Right Cessation
- 2002-01-02 AU AU2002249893A patent/AU2002249893B2/en not_active Expired
- 2002-01-02 WO PCT/US2002/000050 patent/WO2002062207A2/en active IP Right Grant
- 2002-01-02 CA CA2440978A patent/CA2440978C/en not_active Expired - Lifetime
- 2002-01-02 EP EP02718773.1A patent/EP1353666B1/en not_active Expired - Lifetime
-
2005
- 2005-12-20 US US11/313,012 patent/US9164095B2/en not_active Expired - Fee Related
-
2007
- 2007-05-25 US US11/753,799 patent/US9170260B2/en not_active Expired - Fee Related
-
2010
- 2010-10-25 US US12/911,425 patent/US9140703B2/en not_active Expired - Fee Related
-
2011
- 2011-07-14 US US13/183,165 patent/US20110287449A1/en not_active Abandoned
-
2015
- 2015-01-07 US US14/591,381 patent/US9612242B2/en not_active Expired - Lifetime
- 2015-12-30 US US14/984,072 patent/US9435808B2/en not_active Expired - Lifetime
-
2016
- 2016-04-22 US US15/135,757 patent/US9581597B2/en not_active Expired - Fee Related
- 2016-04-22 US US15/135,730 patent/US9575065B2/en not_active Expired - Fee Related
- 2016-04-22 US US15/135,743 patent/US20160238604A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9575065B2 (en) | 2017-02-21 |
CA2440978C (en) | 2013-04-02 |
US20110287449A1 (en) | 2011-11-24 |
EP1353666B1 (en) | 2013-07-03 |
DK1353666T3 (da) | 2013-10-14 |
WO2002062207A2 (en) | 2002-08-15 |
EP1353666A2 (en) | 2003-10-22 |
EP1353666A4 (en) | 2004-03-31 |
US20160238604A1 (en) | 2016-08-18 |
US20110152224A1 (en) | 2011-06-23 |
US20160238603A1 (en) | 2016-08-18 |
US20150185217A1 (en) | 2015-07-02 |
WO2002062207A3 (en) | 2002-10-31 |
US9581597B2 (en) | 2017-02-28 |
US9435808B2 (en) | 2016-09-06 |
US9170260B2 (en) | 2015-10-27 |
AU2002249893B2 (en) | 2007-05-24 |
CA2440978A1 (en) | 2002-08-15 |
US20060105408A1 (en) | 2006-05-18 |
US9164095B2 (en) | 2015-10-20 |
US20080009020A1 (en) | 2008-01-10 |
US20160238605A1 (en) | 2016-08-18 |
ES2429528T3 (es) | 2013-11-15 |
US7223552B2 (en) | 2007-05-29 |
US20160109448A1 (en) | 2016-04-21 |
US9140703B2 (en) | 2015-09-22 |
US20020164662A1 (en) | 2002-11-07 |
US9612242B2 (en) | 2017-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0206273A (pt) | testes diagnósticos para caracterizar o risco de um paciente humano de desenvolver ou apresentar doença cardiovascular e para avaliar um agente terapêutico para doença cardiovascular em um sujeito suspeito de apresentar ou apresentando doença cardiovascular, e, kit | |
Landi et al. | Age-related variations of muscle mass, strength, and physical performance in community-dwellers: results from the Milan EXPO survey | |
Eskin | Reliability of the Turkish version of the perceived social support from friends and family scales, scale for interpersonal behavior, and suicide probability scale | |
Sakai et al. | Tongue strength is associated with grip strength and nutritional status in older adult inpatients of a rehabilitation hospital | |
Leon et al. | A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression | |
Fukunishi et al. | Is alexithymia a culture-bound construct? Validity and reliability of the Japanese versions of the 20-item Toronto Alexithymia Scale and modified Beth Israel Hospital Psychosomatic Questionnaire | |
Neri et al. | The association between body adiposity measures, postural balance, fear of falling, and fall risk in older community-dwelling women | |
Lu et al. | Age-and sex-related differences in muscle strength and physical performance in older Chinese | |
Chicharro-Luna et al. | Variability in the clinical diagnosis of diabetic peripheral neuropathy | |
Klotz et al. | Development of a German version of the oral health assessment tool | |
Heikkilä et al. | Fear of patients related to coronary arteriography | |
Alemán-Mateo et al. | Elderly Mexicans have less muscle and greater total and truncal fat compared to African-Americans and Caucasians with the same BMI | |
Choi et al. | A new severity predicting index for hemorrhagic shock using lactate concentration and peripheral perfusion in a rat model | |
Ozturk et al. | Validity and reliability of the turkish" patient-rated wrist evaluation" questionnaire | |
Denvall et al. | Replication and construct validation of the Barrow Neurological Institute Screen for Higher Cerebral Function with a Swedish population | |
Raggi et al. | Triaxial accelerometer can quantify the Lachman test similarly to standard arthrometers | |
Cantero-Téllez et al. | Effect of muscle strength and pain on hand function in patients with trapeziometacarpal osteoarthritis. A cross-sectional study | |
Alp et al. | Evaluation of patellar tendon with shear wave elastography after anterior cruciate ligament reconstruction using hamstring tendons | |
Shacham et al. | Anxiety or pain: What does the scale measure? | |
Fjeldstad et al. | Vascular function and multiple sclerosis | |
Rom et al. | Body composition in heavy smokers: comparison of segmental bioelectrical impedance analysis and dual-energy X-ray absorptiometry | |
Reschechtko et al. | Postural sway is not affected by estrogen fluctuations during the menstrual cycle | |
Gonzales et al. | Exercise-induced shear stress is associated with changes in plasma von Willebrand factor in older humans | |
Nikolic et al. | Association of von Willebrand factor blood levels with exercise hypertension | |
Kush et al. | Acute dually diagnosed inpatients: The use of self-report symptom severity instruments in persons with depressive disorders and cocaine dependence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2342 DE 24-11-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |